completed

ZePharma - Process development and automation for the preclinical phase of new drug discovery

The objective of the project is to analyze libraries of molecules provided by collaborating entities with a view to discovering molecules with cardioprotective and anti-tumor therapeutic actions.

Start – End dates: 01/01/17-31/12/17

Project reference: Neotec 2016 (SNEO-20161362)

Total budget: 609,144€

Funding agency: CDTI, Spain

¨Funded by CDTI with support from the Ministry of Economy, Industry and Competitiveness; program Innoglobal, project reference: SNEO-20161362¨

Partners:

Summary:

The project consists of the beginning of the drug discovery phase and the ZeGlobalTox and ZeOncoTest / STEM-ZeOncoTest projects that aim to develop technologies for the characterization of toxicity and efficacy parameters of molecules in order to find out their therapeutic potential will be complete. Thus, the objective of the project is to analyze libraries of molecules provided by collaborating entities (CSIC, Pivot Park Center, LEITAT) with a view to discovering molecules with:

  • Cardioprotective therapeutic action. Through the technology developed in the ZeGlobalTox project and the analysis of around 100 molecules provided by the CSIC of Granada, molecules with cardioprotective potential will be sought.
  • Anti-tumor therapeutic action. Using the technology developed in the ZeOncoTest / STEM-ZeOncoTest project and the analysis of the molecules provided by LEITAT, therapeutic immunological agents belonging to the Nanobodies family will be sought.

The expected results are to protect those molecules and nanobodies with therapeutic effects of interest with a view to their subsequent licensing to companies in the pharmaceutical sector for the development of new drugs.

Did you find this article interesting?
Let us know your opinion about it

Leave a Reply

Your email address will not be published. Required fields are marked *